NRSN – neurosense therapeutics ltd. (US:NASDAQ)
Stock Stats
News
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at Zacks Research to a "hold" rating.
Form 6-K NeuroSense Therapeutics For: Dec 04
Form 424B3 NeuroSense Therapeutics
Form EFFECT NeuroSense Therapeutics
Form 6-K NeuroSense Therapeutics For: Nov 24
Form 6-K NeuroSense Therapeutics For: Nov 21
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.